Pharmacovigilance – News and Features

Southern Illinois University’s researchers presented the results of a study using nab-paclitaxel and bevacizumab to treat lymphatic and pulmonary metastases in female SCID mice.

The Company finalized its Phase IIb Oxycyte clinical trial and plans to initiate three pre-clinical animal studies in sickle cell disease, spinal cord injury and stroke in the first half of 2008.

Alliance will accelerate launch of new animal-free supplements and provide customers with a source of high performance cell culture products.

A mouse resistant to cancer, even highly-aggressive types, has been created by researchers at the University of Kentucky. The breakthrough stems from a discovery by UK College of Medicine professor of radiation medicine Vivek Rangnekar and a team of researchers who found a tumor-suppressor gene called "Par-4" in the prostate.

Measures to protect astronauts from health risks caused by space radiation will be important during extended missions to the moon or Mars, say researchers.

The Company adds promising phase II neurology candidate and receives $8.1 million financing in connection with acquisition.

Human trial with GRN163L follows preclinical data showing single-agent activity against multiple myeloma cancer stem cells and cancerous plasma cells.

The breakthrough stems from a discovery by a UK College of Medicine professor and a team of researchers who found a tumor-suppressor gene called "Par-4" in the prostate.

SD118 has commenced a multiple dose ascending Phase I study and the initial single ascending dose Phase I study to explore higher doses has been extended.

Three companies offering genomic services in Germany, Japan and the USA have joined the Eurofins Group this week.